CORPORATE PHILOSOPHY · SINCE 2014 · PIC/S GMP CERTIFIED
12 Years of Stable Supply System
Ensuring Trust in Every Single Dose
Racing Every Second, Sustaining Excellence for 15 Years.
Racing Every Second. High Standards for 15 Years.
Since achieving PIC/S GMP certification in 2014, Petpharmbio has built a resilient radiopharmaceutical supply system. In a clinical environment where radiopharmaceuticals are calculated down to the minute, we ensure every dose is delivered on time, with consistent quality, and full traceability through process standardization, dual-system redundancy, and real-time transit tracking.
Vision & Mission
Vision & Mission
We are more than a pharmaceutical manufacturer—we are an essential cornerstone ensuring diagnostic precision across Taiwan's nuclear medicine system.
VISION
A Reliable Supply Network Powering Nuclear Medicine Diagnostics
In nuclear medicine, supply stability directly impacts diagnostic workflows and clinical interpretation. Petpharmbio provides consistent and predictable pharmaceutical support, allowing physicians to focus entirely on diagnosis without supply uncertainty.
MISSION
Institutionalizing GMP Governance to Guarantee Uninterrupted Supply
We embed PIC/S GMP standards into daily manufacturing, combining in-house cyclotrons, dual-system redundancy, and tungsten container tracking systems. From production and packaging to logistics, every dose is fully monitored and traceable to guarantee supply stability and product quality.
Business Objectives
Business Objectives
The following five strategic objectives highlight Petpharmbio's commitment to expanding supply capacity, operational safety, and R&D innovation.
01
Expand Service Coverage and Routine Supply Volume
Enhance supply coverage and logistics efficiency through new facility capacity expansion and regional network optimization.
02
Establish an Uninterrupted Supply Network
Implement equipment redundancy and real-time monitoring to mitigate disruption risks and maintain clinical continuity.
03
Strengthen R&D Capabilities and Expand Product Pipeline
Invest in therapeutic and diagnostic radiopharmaceuticals such as Lu-177 and Ga-68 to systematically broaden our portfolio.
04
Reduce Radiation Exposure to Protect Workforce Safety
Minimize occupational radiation exposure through fully automated, closed-loop processing systems to maintain a zero-incident safety record.
05
Deepen Academic Collaborations and Industry Partnerships
Build long-term industry-academic partnerships with medical schools, nuclear medicine societies, and international research institutions to cultivate talent and drive globalization.
Recent Developments
Recent Developments
Every milestone serves as the foundation for our next decade of growth.
Timeline
2026
Q3
Q3
● ONGOING
Planning TPEx Mainboard Listing Application
In line with corporate strategic growth, preparations for the TPEx Mainboard listing application are underway, with formal filing scheduled for Q3 as we advance toward new capital market milestones.
Timeline
2026
Q2
Q2
● COMPLETED
Groundbreaking of Miaoli Plant & Acquisition of Lemen Bioscientific Co., Ltd.
Designed by renowned architect Ricky Liu, construction of the new Miaoli Zhunan pharmaceutical facility officially broke ground, marking the start of our next-generation manufacturing hub. Concurrently, the 100% acquisition of Lemen Bioscientific Co., Ltd. was completed, finalizing dual-plant integration in northern and central Taiwan.
Pipeline
2026
R&D
R&D
● ONGOING
Major R&D Breakthroughs
18F-FBPA, an investigational agent for Boron Neutron Capture Therapy (BNCT), received TFDA approval for clinical trials, marking a regulatory milestone in innovative radiotherapeutics. Evaluation and development of radiolabeled pipelines, including AV-133 and TB161 PSMA I&T, continue to progress smoothly.
Latest
2025
09
09
● COMPLETED
Strategic Withdrawal of TIB Listing Application
To align with long-term strategic planning, operational adjustments, and mainboard listing strategy, the decision was made to voluntarily withdraw the Innovation Board (TIB) application to refine documentation in preparation for direct listing on the TPEx Mainboard.
Timeline
2025
03
03
● COMPLETED
IBA Cyclotron Integration | Enhancing Capacity & Stability
Successfully integrated the CYCLONE® IKON cyclotron system, expanding radioisotope production capacity while reinforcing process stability and supply flexibility.
Timeline
2024
09
09
● COMPLETED
Xinzhuang GMP Plant Operational Separation
Inaugurated corporate administrative headquarters, separating operational management from cleanroom production. This structural division allows manufacturing sites to focus on quality control while administrative operations handle regulatory filings and investor relations.
Timeline
2024
07
07
● COMPLETED
Official Emerging Stock Market Listing (Ticker: 7762)
Approved by TPEx as a public company, trading commenced on the Emerging Stock Market under ticker 7762 on July 25. This landmark achievement enhances corporate transparency and provides financial momentum for new facility construction.
Timeline
2024
03
03
● COMPLETED
Initiation of Miaoli Zhunan Plant Construction
Secured land rights for the Miaoli Zhunan plant and advanced engineering design in compliance with PIC/S GMP standards. Upon completion, the facility will significantly increase manufacturing capacity to support supply goals for the next decade.
2014
ASIA FIRST PRIVATE GMP
8
TFDA DRUG APPROVALS
15+
YEARS SUPPLY RECORD
Racing Every Second, Sustaining Excellence for 15 Years.
Racing Every Second. High Standards for 15 Years.
Unwavering Supply Reliability Built on Years of Systems Capabilities and Manufacturing Expertise.
Behind Every Single Dose Lies Petpharmbio's Uncompromising Commitment to Clinical Healthcare.